LZZ Consolo, P Melnikov, FZ Cô nsolo, VA Nascimento and JCDV Pontes BACKGROUND/OBJECTIVES: Zinc is known as an essential micronutrient for human health because of its structural and biochemical functions, influencing growth and affecting multiple aspects of the immune system. Zinc has been extensively studied in neoplastic processes but its role in children with leukemia still remains to be elucidated in several aspects. The aim of this study was to evaluate the effects of oral zinc supplementation on weight gain and infectious episodes in children and adolescents with acute leukemia. SUBJECTS/METHODS: This study included 38 patients, and was carried out as a randomized, double-blind, placebo-controlled investigation. The dosage of plasma zinc levels and the evaluation of nutritional status were performed during a period of 60 days. Zinc was supplemented orally, 2 mg/kg/day, in the form of amino acid salt.
INTRODUCTION
Zinc is known as an essential micronutrient for human health because of its structural and biochemical functions at cellular and subcellular levels, influencing growth and affecting multiple aspects of the immune system. [1] [2] [3] It is known that even a marginal zinc deficiency may be accompanied by an imbalance of T helper type 1 and 2 cells. The beneficial effects of its supplementation in children in the management of infantile diarrhea, acute respiratory infections and pneumonia are evidenced by decreased morbidity and mortality. 4, 5 Zinc supplementation manifests significant positive effects on linear growth, especially when administered alone, and hence it was strongly recommended in the National Health Service strategies in order to reduce stunting in children o5 years of age. 6 It was logical to believe that zinc might also be useful in patients undergoing chemotherapy for acute leukemia and its consecutive complications. So far, at least two zinc compounds were shown to have the activity of their own in acute myeloid leukemia. The former is pyrithione zinc, which appears to possess the potential to directly suppress neoplastic activity, 7 and the latter is zinc ascorbate, proposed to diminish deleterious effects of chemotherapy in children. 8 As for the chemotherapy complications, infections and mucosal damage can be mentioned.
The purpose of the present investigation was to evaluate the effects of oral zinc supplementation on weight gain and infectious episodes in children and adolescents with acute leukemia. Special attention was given to the simultaneous nutritional assessment of the patients.
SUBJECTS AND METHODS
A double-blind, placebo-controlled study was conducted in children within the age interval of 1-18 years, of both genders, who had a previously established clinical and laboratorial diagnosis either of lymphocytic or myeloid leukemia. They were undergoing chemotherapy, according to the established protocols for this disease, at the Regional Hospital 'Rosa Maria Pedrossian', in Campo Grande, MS, Brazil, from March 2010 through February 2012. The following exclusion criteria were applied in order to select the participants: acute infectious disease, renal failure, postsurgery status or usage of any zinc-containing drug. An informed written consent was obtained from the parents or person responsible before enrollment. The project has been duly approved by the Ethical Committee of Federal University of Mato Grosso do Sul.
Data on anthropometric parameters, nutritional status and plasma zinc concentration were collected at the beginning of supplementation (T 0 ), 30 days later (T 30 ) and 60 days later (T 60 ). The classification of the nutritional status was based on the body weight, stature, arm circumference-for-age and triceps skinfold-for-age. [9] [10] [11] In addition, xerostomy, taste dysfunction, nausea and vomiting were registered weekly for a period of 60 days. These data were taken from medical records or provided by parents. As for the episodes of mucositis or clinically diagnosed infections, these were referred up to a broader period of 120 days (T 120 ).
A total of 38 patients were randomized into two groups: one was given orally placebo syrup containing no zinc (group A, n ¼ 18) and the other group (group B, n ¼ 20) received syrup containing zinc in the form of a chelate solution (10 mg/ml). In total, group B was given 2 mg/kg/day of zinc (maximum 60 mg/day) in two divided doses. The packages were identical in color, taste, odor and appearance. Both syrups were manufactured by a single pharmacy. Zinc chelate was purchased from the Pharmanostra Laboratory (Anápolis, Brazil). The bottles were randomly labeled as A for placebo group and B for zinc group by a pharmacist not involved in the study. Neither the researchers nor the participants had any previous knowledge regarding the content of the bottles. All the children who participated in the study took the syrup for 60 days.
For plasma zinc analysis, blood samples were collected in polypropylene syringes and immediately transferred to vacuum tubes free of trace elements (BD Vacutainer Systems-Becton, Dickinson and Company, São Paulo, Brazil). The plasma was separated by centrifugation and stored at À 18 1C for later analytical determinations.
All materials, plastic or glass were previously treated for decontamination of any possible contaminant. The calibration curves were constructed using four different zinc concentrations with values in the range of 0.25-2.0 mg/l. Atomic absorption analyses for plasma zinc were performed with a PerkinElmer AA100 spectrometer (Waltham, MA, USA).
The statistical analysis was carried out using mean±s.d., Student's t-test, Pearson's correlation, Fisher's test, w 2 test and analysis of variance. Data were analyzed using BioEstat, Version 5.0 statistical package (Minneapolis, MN, USA). The value of 'P' adopted was p0.05.
RESULTS
In group A, 83.3% (n ¼ 15) had acute lymphocytic leukemia and 16.7% (n ¼ 3) had acute myelocytic leukemia. In group B, 80% (n ¼ 16) had acute lymphocytic leukemia and 20% (n ¼ 4) had acute myelocytic leukemia. No difference was observed according to diagnosis between the two groups (P ¼ 0.937). There were 53% (n ¼ 20) male and 47% (n ¼ 18) female patients. The mean age in both groups was 9.9 ± 5.5 years. There were no significant differences between both groups according to age (P ¼ 0.328), gender (P ¼ 0.213), weight (P ¼ 0.609) and height (P ¼ 0.38) at T 0 . Table 1 shows the initial assessment of nutritional status of the participants. This status of the patients was found inadequate in 28.9% of diagnosis. A significant difference was observed between the groups according to weight gain at T 30 and T 60 . The weight gain of 2000 g for B group was higher than that observed for group A. For group A, the weight gain was 100 g, showing a significant difference (P ¼ 0.032). As for height values, no significant differences were observed between the groups A and B.
The plasma zinc concentrations at different periods are shown in Table 2 . There were no significant differences for both groups A and B at T 0 (P ¼ 0.16). Group A showed no differences between T 0 and T 30 and between T 30 and T 60 (P ¼ 0.22), whereas group B showed significant differences between T 0 and T 30 (P ¼ 0.004), but no changes occurred from T 0 to T 60 (P ¼ 0.217). There were no significant difference in zinc plasma concentrations between the experimental and placebo groups (P ¼ 0.30).
As for the presence of xerostomy, taste dysfunction, nausea and vomiting, despite that children in group B showed these symptoms to a lesser degree, it was not statistically different from group A (P ¼ 0.812).
In group A, eight patients and in group B 6 patients developed mucositis, with no statistical difference between the groups (P ¼ 0.923). It was observed that with respect to T 120 , in 10 cases the children in group A developed the following infections: gastroenteritis, sinusitis, perianal abscess, pneumonia, herpes zoster, perineal moniliasis and sepsis. At the same time, four cases in group B corresponded to conjunctivitis, cellulites of the leg, pneumonia and sepsis. There was a significant difference between group A and group B regarding infectious episodes (P ¼ 0.02).
DISCUSSION
This study was undertaken in order to evaluate the effects of zinc supplementation in children with acute leukemia. The strengths of this study include a randomized double-blind design and similarity of the patients' characteristics in both groups considered, that is, gender, age and established diagnosis.
Zinc has been extensively studied in neoplastic processes but its role in children with leukemia still remains to be elucidated in several aspects. As a matter of fact, this study showed an improvement in the outcome of children with zinc supplementation, regarding weight and episodes of infection.
A mild to severe nutritional depletion can be present in B11-50% of children with leukemia before treatment, thus influencing the course and prospects for patients' improvement. [11] [12] [13] [14] [15] This large variation is because of several factors such as socioeconomic status and educational and cultural background of children's family, beyond the disease itself. 16 In malnourished children a decreased tolerance to chemotherapy is well known. It comprises an increased infection rate, which contributes to a poor outcome of the disease. 13, 17 A meta-analysis to assess the effects of zinc supplementation on physical growth of children revealed a highly positive response in weight and height increments. 18 This study showed that 28.9% of the patients needed a nutritional intervention at the moment of the first evaluation, bearing in mind the malnourished status and the consumptive characteristic of leukemia. According to the 'Laboratory Tests of Nutritional Status', 19 plasma zinc concentrations observed in these children may be considered as low. They are close to those recently found in pediatric acute lymphoblastic leukemia and non-Hodgkin's lymphoma. 20 The children of zinc-supplemented group had a significant weight gain of B2 kg during the study. Weight gain in children without leukemia has been reported. 21 In this work, it is an important achievement, taking into account the severity of their blood disorder. It means that despite an increase in plasma zinc concentrations observed in group B for a shorter period (T 0 -T 30 ), clear clinical effects were evident for a longer time.
It has been reported for adults that age-related decline in taste acuity may be both a cause and an effect of depleted zinc. 22 In this study the presence of xerostomy, taste dysfunction, nausea and vomiting were observed in both groups, but with less intensity in group B. All these symptoms may have affected food choices and are factors directly related to weight changes in children with leukemia.
In agreement with a previous trial, 23 in cases of chemotherapyinduced mucositis, a significant difference in plasma zinc Zinc supplementation in leukemia LZZ Consolo et al concentrations before and after supplementation could not be proved. In clinical practice with trace elements, medical personnel and researches are inclined to make a logical connection between higher concentration of an ion and the consecutive effect. When this does not happen, a larger number of observations are needed to prove the fact. Hence, the most important outcome of this study was to confirm again that the plasma levels of zinc are insensitive to supplementation. The reasons for this repeated finding are unclear but, at least partially, it might be because of the rigorous zinc homeostasis. 24 It is also possible that the mineral can be rapidly redistributed among other tissues in response to metabolic needs or retained in liver for accelerated protein synthesis, in the form of zinc-thymulin and other complexes. 25 As for the management of mucositis, there have been many studies dedicated to its prevention and treatment 22, 26, 27 including zinc supplementation. As zinc is a substantial element for collagen synthesis, for fibroblast and keratinocyte proliferation, it is expected to enhance the re-epithelialization rate in wound healing process. Hence, it could be effective in prevention of severe mucosal damage resulting from chemotherapy. [28] [29] [30] [31] Some authors attribute a positive role of zinc sulfate when treating the patients with head and neck cancer undergoing radiotherapy. In particular, it was mentioned to be effective in the reduction of severity of oral mucositis. 31, 32 Nevertheless, there is no consensus on the direct clinical improvements as a result of zinc supplementation. 23, 33 This study strengthens this opinion as the frequency of mucositis occurrences in both groups, given zinc chelate and placebo, was not statistically different.
As for the infection episodes, zinc efficiency is well established as an essential element for normal immune function, and hence even a slight decrease in zinc status may weaken the immune response, increasing infection occurrences. 34, 35 It has been reported, for example, that zinc supplementation attenuates the symptoms of common cold, can accelerate recovery from pneumonia and other bacterial diseases and reduces diarrhea morbidity. 4, 5, 36 Besides, it is well known that during chemotherapy, a risk for such complications becomes higher, sometimes leading to treatment discontinuation. In adult patients receiving radiotherapy, oral zinc supplementation prevents opportunistic bacterial and fungal infections. 32 To the best of our knowledge, the literature data regarding children population are practically inexistent. In this paper, we have shown that the zinc supplementation could have actually reduced the number of infectious episodes. This effect was found to be evident after 30 days of supplementation and kept on for at least 120 consecutive days.
In conclusion, it has become evident from this study that from the clinical point of view supplementary zinc produces a positive effect upon nutritional status as a whole, and reduces the infectious episodes. To a certain extent, zinc supplementation also prevents some of the deleterious effects of chemotherapy in children with leukemia, improving their quality of life.
